<DOC>
	<DOCNO>NCT00266097</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high-energy x-ray kill tumor cell . Giving oxaliplatin together gemcitabine , erlotinib , radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose oxaliplatin , gemcitabine , erlotinib give together radiation therapy treat patient unresectable and/or metastatic pancreatic cancer biliary tract cancer .</brief_summary>
	<brief_title>Oxaliplatin , Gemcitabine , Erlotinib , Radiation Therapy Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer Biliary Tract Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) oxaliplatin gemcitabine hydrochloride combine radiotherapy patient unresectable and/or metastatic pancreatic biliary tract adenocarcinoma . ( Part 1 ) - Determine MTD erlotinib hydrochloride gemcitabine hydrochloride combine oxaliplatin MTD radiotherapy patient . ( Part 2 ) OUTLINE : This multicenter , nonrandomized , parallel group , uncontrolled , open-label , dose-escalation study gemcitabine hydrochloride , oxaliplatin , erlotinib hydrochloride . - Part 1 : Patients receive gemcitabine hydrochloride IV 30-60 minute oxaliplatin IV day 1 . Patients also undergo external beam radiotherapy ( EBRT ) daily day 1-5 . Treatment repeat every 7 day 6 course . Cohorts 3-6 patient receive escalate dos gemcitabine hydrochloride oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . Up 10 patient treated MTD . - Part 2 : Patients receive gemcitabine hydrochloride , oxaliplatin* , EBRT part 1 . Patients also receive oral erlotinib hydrochloride daily day 1-5 . Treatment repeat every 7 day 6 course . Cohorts 3-6 patient receive escalate dos gemcitabine hydrochloride erlotinib hydrochloride MTD determine . The MTD define dose precede 2 3 2 6 patient experience DLT . Up 10 patient treated MTD . NOTE : *Patients receive oxaliplatin MTD determine part 1 . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy confirm diagnosis following : Pancreatic carcinoma Ampullary carcinoma Biliary tract ( gallbladder bile duct ) carcinoma Unresectable and/or biopsyproven metastatic disease Suitable bimodality therapy , determine medical oncologist radiation oncologist PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 2 month ANC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Creatinine &lt; 1.5 mg/dL Total bilirubin &lt; 2 time upper limit normal ( ULN ) AST &lt; 3 time ULN ( &lt; 5 time ULN liver metastasis present ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity platinum agent gemcitabine hydrochloride No serious medical psychiatric illness would preclude give informed consent PRIOR CONCURRENT THERAPY : No prior radiotherapy upper abdomen More 3 week since prior chemotherapy No prior erlotinib hydrochloride At least 5 day since prior concurrent CYP3A4 inducer/inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
</DOC>